Trial Profile
Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer (additional resaerch B)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2019
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results evaluating tumor sidedness and enriched gene groups presented at the 42nd European Society for Medical Oncology Congress
- 28 Nov 2016 New trial record